Research use onlyFor laboratory and research purposes only — not for human consumption, medical, veterinary or diagnostic use.

PeptideStacks
Immune Support

BPC-157 + KPV + Thymosin α-1 Immune Research Stack

Three-peptide immune-modulatory research stack combining gut barrier (BPC-157), NF-κB suppression (KPV) and T-cell maturation support (Thymosin α-1).

3 peptides 6-week cycle intermediate
Gut barrierAnti-inflammatory toneT-cell maturation research

The immune system does not fail at a single point — it fails across interconnected layers. Gut barrier dysfunction floods the systemic circulation with antigenic material, driving innate immune overactivation; chronic NF-κB signalling sustains a low-grade cytokine tone that exhausts effector cells; and impaired thymic output leaves the adaptive arm under-resourced for antigen-specific responses. Most research interventions target one of these layers in isolation. This three-peptide stack — BPC-157, KPV, and Thymosin α-1 — is designed to address all three simultaneously, providing a sequenced research model that spans the full innate-to-adaptive immune axis. All three compounds are unapproved research peptides in the UK; this page summarises published preclinical and limited clinical findings on each mechanism, not a clinical protocol.

Why three peptides for immune research?

Single-peptide immune research protocols are limited by the breadth of the immune cascade they can address. BPC-157 acts at the gut-mucosal level, where barrier integrity determines how much exogenous antigenic material enters the portal circulation. A leaky epithelial barrier chronically primes the innate immune system; by supporting tight-junction proteins and promoting mucosal angiogenesis, BPC-157 research models aim to reduce this upstream antigenic load [PMID:21548867].

KPV — the C-terminal tripeptide Lys-Pro-Val, derived from alpha-melanocyte-stimulating hormone (α-MSH) — operates at the cytokine signalling layer. It suppresses NF-κB nuclear translocation and downregulates pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) in intestinal epithelial and macrophage cell lines [PMID:18612141]. Its oral stability makes it uniquely tractable for gut-targeted research.

Thymosin α-1, the 28-amino-acid peptide first isolated and characterised by Allan Goldstein at George Washington University in the 1970s, works at the adaptive arm. It promotes T-cell maturation in the thymus, activates dendritic cells, and augments NK-cell function — downstream effects that are only possible once innate inflammation has been adequately resolved [PMID:19392576]. Together, these three peptides address distinct, sequential nodes within a single cascade rather than overlapping targets within the same pathway.

Mechanism of action — each peptide

BPC-157 — mechanism of action

BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic pentadecapeptide derived from a human gastric juice protein. Its immunological relevance is primarily upstream: by preserving gut mucosal integrity, it reduces the antigenic stimulus that drives chronic innate immune activation.

In published rodent models, BPC-157 supports mucosal barrier function through several documented mechanisms [PMID:21548867]:

  • VEGFR2 upregulation in intestinal endothelium, increasing mucosal capillary density and supporting nutrient and oxygen delivery to epithelial repair.
  • Nitric oxide system modulation — cytoprotective against both NO excess and deficiency. This bidirectional stabilisation is particularly relevant in IBD-model research, where NO dysregulation contributes to mucosal breakdown.
  • Attenuation of NSAID- and corticosteroid-induced intestinal damage in rat models, with documented reduction in permeability markers [PMID:20166987].
  • Stabilisation of tight-junction protein expression (ZO-1, occludin) under inflammatory challenge — the direct mechanism by which reduced systemic antigenic load is proposed to occur.

BPC-157 is stable in human gastric juice, supporting its use by oral route for gut-targeted research applications. Its short plasma half-life necessitates twice-daily administration in subcutaneous research protocols.

KPV — mechanism of action

KPV (Lys-Pro-Val) is the biologically active C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). α-MSH was identified as a potent endogenous anti-inflammatory neuropeptide; Brzoska and colleagues established that much of its anti-inflammatory activity resides in the C-terminal tripeptide [PMID:18612141], which retains NF-κB suppressive capacity while offering superior stability and oral bioavailability relative to the full heptadecapeptide.

KPV's primary immunological mechanism is inhibition of NF-κB nuclear translocation in intestinal epithelial cells and macrophages. Downstream consequences documented in cell and animal models include:

  • Suppression of IL-6, IL-1β, and TNF-α — the canonical pro-inflammatory triad — without the broad immunosuppression associated with corticosteroids.
  • Downregulation of ICAM-1 expression on endothelial cells, reducing leukocyte recruitment to inflamed gut mucosa.
  • Direct anti-inflammatory activity in IBD models — Kannengiesser et al. demonstrated that oral and intracolonic KPV reduced histological inflammation scores in murine DSS-colitis and IL-10-knockout models [PMID:17941073].
  • Oral stability — KPV resists gastric acid degradation sufficiently to exert luminal and mucosal effects when administered orally, a pharmacokinetic advantage over most peptides in this stack category.

In the context of this stack, KPV's role is to suppress the NF-κB-mediated cytokine amplification that would otherwise counteract the downstream immunomodulatory signal from Thymosin α-1. Suppressing IL-6 and TNF-α tone creates a permissive environment for T-cell maturation and dendritic-cell function.

Thymosin α-1 — mechanism of action

Thymosin α-1 (Tα1) is a 28-amino-acid acetylated peptide first isolated from calf thymus by Allan Goldstein and colleagues at George Washington University in 1977 — part of the broader Thymosin Fraction 5 programme that established the thymus as a primary immunoendocrine organ. The synthetic form, Thymalfasin (trade name Zadaxin), has received regulatory approval in more than 30 countries for hepatitis B and C treatment, representing the most clinically validated peptide in this stack. It is not approved in the UK or USA, where it remains a research compound only.

Enrico Garaci and colleagues at the Italian National Institute of Health produced a substantial body of preclinical and translational research establishing Tα1's mechanistic profile [PMID:11137613]:

  • T-cell maturation and thymic education — Tα1 acts on immature thymocytes to promote differentiation toward mature CD4+ and CD8+ effector phenotypes. In thymic atrophy models, exogenous Tα1 partially restores the mature T-cell output that is lost with age-related thymic involution.
  • Dendritic-cell activation — Romani et al. demonstrated that Tα1 activates plasmacytoid dendritic cells through TLR7/TLR9-dependent pathways, increasing IFN-α secretion and linking innate pattern recognition to adaptive priming [PMID:17600289].
  • NK-cell augmentation — preclinical data and clinical hepatitis trials document increased NK activity, particularly relevant in viral and oncological research contexts.
  • Regulatory T-cell modulation — at physiological concentrations, Tα1 promotes Treg function and tolerance, not immune overactivation; this bidirectional regulatory capacity explains its safety profile across broad patient populations in approved markets [PMID:20536461].

In this stack, Thymosin α-1 is positioned as the adaptive-arm amplifier, acting most effectively after BPC-157 has reduced upstream antigenic pressure and KPV has attenuated the cytokine environment.

Summarised studies on the combination

No single published study has examined all three peptides in formal combination. The evidence base for this stack is therefore constructed from overlapping monotherapy and pairwise literature, with mechanistic rationale for non-redundancy at each node.

BPC-157 in gut-immune models — Sikiric and colleagues have published extensively on BPC-157's capacity to restore intestinal barrier function in NSAID-enteropathy, corticosteroid-impaired healing, and ethanol-lesion models. The consistent finding is normalisation of permeability markers and attenuation of systemic inflammatory cytokine elevation secondary to gut barrier failure [PMID:21548867]. This positions BPC-157 as the upstream antigenic-load reducer in the stack rationale.

KPV in murine IBD models — Kannengiesser et al. (2008) tested intracolonic and oral KPV in DSS-induced colitis and IL-10-knockout mice. Both routes produced significant reductions in histological damage score, myeloperoxidase activity (a neutrophil infiltration marker), and mucosal TNF-α and IL-1β levels [PMID:17941073]. The oral route was effective at 300–500 µg/kg, consistent with the research dosing used in this protocol.

Thymosin α-1 in hepatitis clinical trials — Naylor and Hadden reviewed T-cell targeted immunotherapy evidence including Zadaxin trials in hepatitis B and C [PMID:12890430]. In multiple Phase II and III studies, Tα1 at 1.6 mg SC twice weekly produced sustained virological response improvements versus interferon monotherapy. The 1.6 mg twice-weekly dose used in approved clinical applications for hepatitis is the most-cited reference point for research protocols — mirrored directly in the dosing table below.

Mechanistic cascade rationale — Romani et al. (2007) established that Tα1's dendritic-cell activation is blunted in high-TNF-α environments, providing direct mechanistic support for the stack sequencing: KPV's NF-κB suppression is not merely additive but potentially permissive for Tα1's adaptive-arm effects [PMID:17600289]. This cascade logic distinguishes the three-peptide combination from independent monotherapy use of any single agent.

The combination has not been evaluated in any registered human clinical trial. All combination rationale is derived from overlapping preclinical literature and mechanistic inference.

Full research protocol

The protocol below mirrors the dosing most commonly cited in the preclinical and clinical source literature. BPC-157 and Thymosin α-1 are administered subcutaneously; KPV is administered orally given its documented oral stability and gut-targeted action.

PeptideDoseFrequencyTimingCycle length
BPC-157500 µgTwice daily SCAM + PM6 weeks
KPV300–500 µgDaily OralEmpty stomach6 weeks
Thymosin α-11.6 mgTwice weekly SCMon + Thu6 weeks

Weekly research timeline

Note: the timeline below mirrors the frontmatter exactly. BPC-157 and Thymosin α-1 each run for four weeks in this protocol; KPV runs for three weeks, reflecting the shorter cytokine-suppression window documented in murine IBD models before adaptive-phase Tα1 signalling is established.

PeptideWk 1Wk 2Wk 3Wk 4Wk 5Wk 6
BPC-157500 µg BID500 µg BID500 µg BID500 µg BID——
KPV500 µg/d500 µg/d500 µg/d———
Thymosin α-11.6 mg 2x1.6 mg 2x1.6 mg 2x1.6 mg 2x——
  • Weeks 1–3 (barrier and cytokine phase): All three peptides are active. BPC-157 begins reducing gut permeability; KPV suppresses NF-κB cytokine tone; Thymosin α-1 begins thymic and dendritic-cell priming in the lower-inflammation environment.
  • Week 4 (adaptive consolidation): KPV is discontinued; BPC-157 and Thymosin α-1 continue. The cytokine environment has been reshaped by this point, allowing Tα1 to drive T-cell maturation without competing pro-inflammatory noise.
  • Weeks 5–6 (observation window): All peptides are discontinued in the protocol as structured. The post-cycle observation period allows assessment of sustained immune tone changes. Thymosin α-1's T-cell effects persist beyond the last injection, consistent with the hepatitis clinical trial washout data.

Reconstitution & storage notes

BPC-157 reconstitutes readily in bacteriostatic water at 1 mg/mL and is stable at 2–8 °C for approximately 30 days; aliquot before freezing if storage beyond 30 days is required. KPV is typically supplied as a lyophilised powder for oral use — it may be dissolved in sterile water or encapsulated; its resistance to gastric degradation makes standard solution administration viable. Thymosin α-1 (Thymalfasin) reconstitutes in sterile water at 1.6 mg per vial (the clinically validated unit dose) and should be used within 24 hours of reconstitution; the lyophilised form is stable at room temperature and at 2–8 °C.

Where to source these research peptides

Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.

For gut-targeted immune research with a mucosal-repair emphasis, see the KPV + LL-37 Gut Healing Stack, which combines KPV's NF-κB suppression with LL-37's antimicrobial and epithelial-repair signalling. For tissue-repair stacks built around BPC-157 in a non-immune context, see the BPC-157 + TB-500 Healing Stack, the most-documented two-peptide repair combination in the published rodent-model literature.

For per-peptide monographs covering each compound's full mechanism, see PeptideAuthority.co.uk/peptides/bpc-157, PeptideAuthority.co.uk/peptides/kpv, and PeptideAuthority.co.uk/peptides/thymosin-alpha-1.

Frequently asked research questions

Each addresses a different node: BPC-157 (mucosal barrier integrity → reduces antigenic load), KPV (cytokine tone), Thymosin α-1 (adaptive T-cell maturation). The combination covers innate-to-adaptive immune research more fully than any single peptide.

References

Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.

  1. Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16) :1612-32 doi:10.2174/138161211796196954 · PMID: 21548867
  2. Sikiric P, Seiwerth S, Brcic L, et al.. Revised Robert's cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2010;16(10) :1224-34 doi:10.2174/138161210790945977 · PMID: 20166987
  3. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5) :581-602 doi:10.1210/er.2007-0027 · PMID: 18612141
  4. Kannengiesser K, Maaser C, Heidemann J, et al.. Melanocyte-stimulating hormone-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3) :324-31 doi:10.1002/ibd.20334 · PMID: 17941073
  5. Garaci E, Pica F, Rasi G, Palamara AT. Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopharmacology. 2000;22(12) :1067-76 doi:10.1016/S0192-0561(00)00073-6 · PMID: 11137613
  6. Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opinion on Biological Therapy. 2009;9(5) :593-608 doi:10.1517/14712590902911412 · PMID: 19392576
  7. Romani L, Bistoni F, Montagnoli C, et al.. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Annals of the New York Academy of Sciences. 2007;1112 :326-38 doi:10.1196/annals.1415.044 · PMID: 17600289
  8. Naylor PH, Hadden JW. T cell targeted immunotherapy of cancer: the receptor for immunospecific T cell signaling. International Immunopharmacology. 2003;3(8) :1205-15 doi:10.1016/S1567-5769(03)00100-X · PMID: 12890430
  9. Tuthill C, Rios I, McBeath R. Thymosin alpha 1: past clinical experience and future promise. Annals of the New York Academy of Sciences. 2010;1194 :130-5 doi:10.1111/j.1749-6632.2010.05490.x · PMID: 20536461